About the Conference
The Trans-Pacific Health Sciences Dialogue is a meeting for C-level biopharmaceutical industry executives and business development executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America.
This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
Take a look at some photos from the 2014 Trans-Pacific Health Sciences Dialogue!
In 2015, the Trans-Pacific Health Sciences Dialogue will be held at:
Joseph B. Martin Conference Center
at Harvard Medical School
77 Avenue Louis Pasteur
Boston, MA 02115
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an event for senior biopharmaceutical executives, KOLs, select industry advisors and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment.
Industry News from FiercePharmaAsia
- More change ahead for Novogen as interim CEO Ross orders wide review of programs
Moving quickly to show investors a change of direction is ahead, Novogen acting Chief Executive Iain Ross announced a company-wide review of its preclinical programs less than a week after the abrupt departure of his predecessor, Graham Kelly.
Industry News from PharmAsia
- More Companies Tapping Direct Sales Route In ChinaUnder the influence of a changing policy environment, China's healthcare companies are experiencing a development bottleneck. The need to upgrade to new business models and finding new ways of doing so have become realities for many companies, and more and more are tapping into the opportunities presented by direct sales, including A-share market-listed and state-owned companies.<img src="http://feeds.feedburner.com/~r/_PharmAsiaNews/~4/v__BUM5ATWs" height="1" width="1" alt="" />